Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
Hosted on MSN17h
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback